These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10466916)

  • 21. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy.
    Calza L; Manfredi R; Farneti B; Chiodo F
    Int J Antimicrob Agents; 2003 Jul; 22(1):54-9. PubMed ID: 12842328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marked hyperlipidaemia on ritonavir therapy.
    Sullivan AK; Nelson MR
    AIDS; 1997 Jun; 11(7):938-9. PubMed ID: 9189227
    [No Abstract]   [Full Text] [Related]  

  • 23. [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].
    Hirsch HH; Battegay M
    Dtsch Med Wochenschr; 2003 May; 128(19):1051-4. PubMed ID: 12736856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Myocardial infarction in the course of antiretroviral therapy with protease inhibitor].
    Buccoliero G; Lonero G; Rollo MA; Cristiano L; Romanelli C; Loperfido P; Chimienti A; Angelini P; Resta F
    Recenti Prog Med; 2003 Jun; 94(6):264-6. PubMed ID: 12793098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
    Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia.
    Brown CA; Lesher JL; Peterson CM
    J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S86-9. PubMed ID: 15858517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.
    Martínez E; Domingo P; Galindo MJ; Milinkovic A; Arroyo JA; Baldovi F; Larrousse M; León A; de Lazzari E; Gatell JM
    Clin Infect Dis; 2004 Apr; 38(7):1017-23. PubMed ID: 15034836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.
    Bongiovanni M; Bini T; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Biasi P; Adorni F; Monforte AD
    AIDS Res Hum Retroviruses; 2006 Feb; 22(2):132-8. PubMed ID: 16478394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).
    Lafeuillade A; Hittinger G; Philip G; Lambry V; Jolly P; Poggi C
    HIV Clin Trials; 2004; 5(6):392-8. PubMed ID: 15682352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.
    Tsiodras S; Mantzoros C; Hammer S; Samore M
    Arch Intern Med; 2000 Jul; 160(13):2050-6. PubMed ID: 10888979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Acute coronary syndromes in patients treated with HIV protease inhibitors].
    Barthélémy O; Escaut L; Vayre F; Gallet B; Pulik M; Heloire F; Vittecoq D
    Presse Med; 2002 Mar; 31(8):343-8. PubMed ID: 11913076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Blood lipid abnormalities during treatment with protease inhibitors].
    Vergès B; Petit JM
    Presse Med; 2001 May; 30(18):911-4. PubMed ID: 11413853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir).
    Rhee MS; Hellinger JA; Sheble-Hall S; Cohen CJ; Greenblatt DJ
    J Clin Pharmacol; 2010 Apr; 50(4):392-400. PubMed ID: 20097936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor.
    de Luis DA; Bachiller P; Aller R
    Nutrition; 2001 May; 17(5):414-5. PubMed ID: 11377136
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.